SecBot SecBot

DRTS drug pipeline

Alpha Tau Medical Ltd. · 1 rated drug
$11.97
−10.5% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
Time to marketThe ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.

Alpha DaRT Updated Nov 15

What to watch

The REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.

Bull case
  • All 8 treated patients in the REGAIN glioblastoma trial remain alive as of Nov 11, 2026, with median overall survival not yet reached at 6.9 months median follow-up, a striking early signal in a uniformly fatal disease. The ReSTART pivotal trial for recurrent cSCC completed enrollment of 88 patients in May 2026, and the first PMA module was submitted to the FDA in January 2026, advancing toward a potential US approval. The head and neck cancer combo study with Keytruda showed a 100% objective response rate (9 evaluable patients) and 18.2-month median overall survival. Analyst consensus is strongly bullish: 4 Strong Buy, 5 Buy, 2 Hold, with a mean price target of $20.60 (54% upside from $13.38). Piper Sandler upgraded to Overweight on Nov 11, 2026, citing a catalyst-rich period. BlackRock doubled its position and UBS added in Q3 2026.
Bear case
  • Alpha DaRT has no FDA approval in the US; the only marketing approvals are in Japan (head and neck cancer) and Israel (SCC of skin and oral cavity), leaving a long and uncertain regulatory path. The REGAIN glioblastoma trial is a small single-arm pilot study (up to 20 patients) that may not support registration. The company is pre-revenue and has accumulated significant losses; while cash was ~$104.8M as of late August 2026, the burn rate may require future dilution. The CFO sold shares (2,871 shares at ~$15, Aug 2026) under a 10b5-1 plan, and several institutional holders trimmed or exited positions in Q3 2026.